Exact Sciences (EXAS, $125.72) to buy Thrive Earlier Detection for $2.5 billion
Molecular diagnostics company Exact Sciences has agreed to buy cancer-detection company Thrive Earlier Detection for $2.5 billion in cash and stock.
Under the terms of the 65% stock-35% cash deal, Thrive Earlier Detection will receive $1.7 billion up front . An additional $450 million will be payable to Thrive subject to milestones related to the development and commercialization of a blood-based, multi-cancer screening test.
Exact Sciences CEO Kevin Conroy said that the acquisition will allow Exact Sciences to add Thrive's early-stage cancer-screening test, CancerSEEK, into its blood-based screening platform.
EXAS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EXAS turned positive on March 20, 2026. Looking at past instances where EXAS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 241 cases where EXAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
EXAS broke above its upper Bollinger Band on March 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Advertisement
General Information
a developer of proprietary technologies for the detection of cancer
Industry MedicalSpecialties
Advertisement